scholarly article | Q13442814 |
P50 | author | James F. Gusella | Q1602688 |
Antoni Castells | Q37839005 | ||
P2093 | author name string | Ramesh V | |
Rustgi AK | |||
P433 | issue | 11 | |
P407 | language of work or name | English | Q1860 |
P304 | page(s) | 2836-2839 | |
P577 | publication date | 2000-06-01 | |
P1433 | published in | Cancer Research | Q326097 |
P1476 | title | A region of deletion on chromosome 22q13 is common to human breast and colorectal cancers | |
P478 | volume | 60 |
Q33867526 | Amplification of D22S283 as a favorable prognostic indicator in liver fluke related cholangiocarcinoma |
Q41432640 | BH3-only protein Bik is involved in both apoptosis induction and sensitivity to oxidative stress in multiple myeloma |
Q37524058 | CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations |
Q36545056 | CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8. |
Q36696688 | Chromosomal analysis of non-small-cell lung cancer by multicolour fluorescent in situ hybridisation |
Q41536811 | Copy number rather than epigenetic alterations are the major dictator of imprinted methylation in tumors |
Q35011398 | Detailed deletion mapping of loss of heterozygosity on 22q13 in sporadic colorectal cancer |
Q34253712 | Expression of parvin-β is a prognostic factor for patients with urothelial cell carcinoma of the upper urinary tract |
Q36859140 | Genome scan study of prostate cancer in Arabs: identification of three genomic regions with multiple prostate cancer susceptibility loci in Tunisians. |
Q38649909 | Impact of CYP2D6 polymorphisms on endoxifen concentrations and breast cancer outcomes. |
Q34762457 | Individuality and variation in gene expression patterns in human blood |
Q36047387 | Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studies. |
Q30396926 | Loss of heterozygosity on long arm of chromosome 22 in sporadic colorectal carcinoma |
Q37589094 | PIK3CA mutations are common in lobular carcinoma in situ, but are not a biomarker of progression. |
Q36421428 | Parvin-beta inhibits breast cancer tumorigenicity and promotes CDK9-mediated peroxisome proliferator-activated receptor gamma 1 phosphorylation |
Q30476046 | Pooled analysis of loss of heterozygosity in breast cancer: a genome scan provides comparative evidence for multiple tumor suppressors and identifies novel candidate regions |
Q37678053 | Prediction of tamoxifen outcome by genetic variation of CYP2D6 in post-menopausal women with early breast cancer |
Q34388828 | Prognostic Impact of del(17p) and del(22q) as assessed by interphase FISH in sporadic colorectal carcinomas. |
Q37039595 | Pten null prostate tumorigenesis and AKT activation are blocked by targeted knockout of ER chaperone GRP78/BiP in prostate epithelium |
Q36386270 | ST13, a proliferation regulator, inhibits growth and migration of colorectal cancer cell lines |
Q30657925 | THetA: inferring intra-tumor heterogeneity from high-throughput DNA sequencing data |
Q37065730 | Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters |
Q38000062 | The bisecting GlcNAc in cell growth control and tumor progression |
Q36325617 | The parvins |
Q33910850 | Type II transmembrane serine protease gene variants associate with breast cancer |
Q35663665 | What we know about ST13, a co-factor of heat shock protein, or a tumor suppressor? |
Search more.